|Committee Member||Employment||Consultant||Speakers Bureau||Ownership/Partnership/Principal||Personal Research||Institutional, Organizational, or Other Financial Benefit||Expert Witness|
|Peter W. F. Wilson (Chair)||Emory University School of Medicine, Department of Medicine||None||None||None||None||None||None|
|Tamar S. Polonsky (Vice Chair)||University of Chicago Medicine||None||None||None||None||None|
|Amit Khera||Assistant Professor of Medicine, University of Texas Southwestern Medical Center||None||None||None||None||None||None|
|Andrzej S. Kosinski||Associate Professor of Biostatistics|
Department of Biostatistics and Bioinformatics
|Jeffrey T. Kuvin||Section Chief, Cardiovascular Medicine, Dartmouth-Hitchcock Medical Center||None||None||None||None||None||None|
|Michael D. Miedema||Director of Cardiovascular Prevention, Minneapolis Heart Institute||None||None||None||None||None||None|
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAPA, American Academy of Physician Assistants; ABC, Association of Black Cardiologists; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; ADA, American Diabetes Association; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASPC, American Society for Preventive Cardiology; PCNA, Preventive Cardiovascular Nurses Association.
↵∗ On March 1, 2018 (after writing of this Systematic Review was complete excepting ODYSSEY OUTCOMES inclusion), Dr. Polonsky, after having reviewed her listing on the CMS Open Payments Data website, realized that she had been a local PI in the STRENGTH trial, supported by AstraZeneca, and promptly reported this to the Task Force. Only 1 patient was recruited, and Dr. Polonsky did not receive any direct salary support, but by ACC/AHA standards, this would constitute a relationship with industry (RWI) and thus, in the interest of full transparency, this footnote has been added.